GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Net Income (Discontinued Operations)

DMK Pharmaceuticals (DMK Pharmaceuticals) Net Income (Discontinued Operations) : $-1.08 Mil (TTM As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. DMK Pharmaceuticals's Net Income (Discontinued Operations) for the three months ended in Sep. 2023 was $0.35 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.08 Mil.

DMK Pharmaceuticals Net Income (Discontinued Operations) Historical Data

The historical data trend for DMK Pharmaceuticals's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Net Income (Discontinued Operations) Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -13.55 -11.23 -0.28

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 0.08 0.07 -1.57 0.35

DMK Pharmaceuticals Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
CSTF PHBI STMH GCAN NEPTF SKYI MJNE CSUI THCT CANB ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ
Traded in Other Exchanges
N/A
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
Website
https://www.adamispharmaceuticals.com
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Executives
Dorbin John W. Jr. officer: General Counsel C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen officer: CFO C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi director, officer: CEO 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi director 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio director 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd director, 10 percent owner, officer: President/CEO PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss officer: Chief Medical Officer 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto officer: Chief Financial Officer 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai director 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins officer: Chief Financial Officer 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels officer: Vice President of Operations 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf director C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams director 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134